This Is MS Multiple Sclerosis Knowledge & Support Community

213 patients were treated during the study period. The study population consisted of 192 patients (mean age 48.5 years; 34% male and 66% female) for a 90% response rate (mean response time 109.4 +/− 39.6 days). MS subtypes included relapsing remitting (RRMS) (n=96), secondary progressive (SPMS) (n=66), and primary progressive (PPMS) (n=30). 189 patients (98.4%) underwent angioplasty (PTA) and 3 patients underwent PTA with stent placement (1.6%); 2.2 vessels were treated per procedure. In the 192 patients, the mean PHS and MHS changed from 43.2 to 52.4 (p<0.05) and from 57.1 to 65.2 (p<0.05) respectively. PHS/MHS improvement was seen in 77%/74% with RRMS, 59%/50% with SPMS, and 77%/70% with PPMS; these changes were all significant (p<0.05). However, SPMS patients were less likely than RRMS and PPMS patients to improve their PHS (p<0.05) or MHS (p<0.05). PHS/MHS improvement was seen in 74%/71% with <5 yrs since dx, 78%/78% with 5-10 yrs since dx, and 66%/60% with >10 yrs since dx; these changes were significant in all groups (p<0.05). However, years since diagnosis was not associated with change in PHS (p=0.239) or MHS (p=0.071).